Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

575

Participants

Timeline

Start Date

April 18, 2020

Primary Completion Date

November 1, 2020

Study Completion Date

November 16, 2020

Conditions
Convalescent Plasma for COVID 19
Interventions
OTHER

convalescent plasma from recovered COVID 19 donor

After obtaining informed consent, Eligible Patients who have severe COVID-19 and have not recovered yet will be infused with the donated convalescent plasma (10-15 ml/kg body weight of recipient)19 at least once \& if possible, daily, for up to 5 sessions.

Trial Locations (14)

Unknown

John Hopkins Aramco Healthcare, Dhahran

Qatif Central Hospital, Al Qaţīf

Dammam Medical Complex, Dammam

Imam Abdulrahman Bin Faisal University, Dammam

king Fahad specialist hospital, Dammam

DHahran Military Medical Complex, Dhahran

International Medical Center, Jeddah

Madinah General Hospital, Madinah

Ohud Hospital, Madinah

Taibah University, Madinah

King Abdulaziz Medical City, Riyadh

King Fahad Medical City, Riyadh

King Faisal Specialist Hospital & Research Center, Riyadh

King Khalid University Hospital, Riyadh

All Listed Sponsors
collaborator

King Fahad Medical City

OTHER_GOV

collaborator

King Faisal Specialist Hospital & Research Center

OTHER

collaborator

King Abdulaziz Medical City

OTHER_GOV

collaborator

King Fahad University Hospital

UNKNOWN

collaborator

John Hopkins Aramco Healthcare

UNKNOWN

collaborator

Taibah University

OTHER

collaborator

King Saud University

OTHER

collaborator

King Khaled University Hospital

UNKNOWN

collaborator

King Fahad Military Medical Complex

UNKNOWN

collaborator

Qatif Central Hospital

OTHER

lead

King Fahad Specialist Hospital Dammam

OTHER

NCT04347681 - Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19 | Biotech Hunter | Biotech Hunter